Vitestro’s Aletta autonomously finds a vein and draws blood in adults, with one trained phlebotomist supervising up to three machines — a possible answer to a worsening staffing shortage.
Ultragenyx’s Genglycos delivers a working gene to the liver in glycogen storage disease type Ia, aiming to free patients from the relentless routine of round-the-clock cornstarch dosing.
The antibody cut new abnormal bone formation by up to 90% in a trial for fibrodysplasia ossificans progressiva — a devastating disorder in which soft tissue slowly turns to bone.
The Dutch biotech will push its brain-signaling drug through a mid-stage trial for cognitive impairment in schizophrenia — a common, disabling problem with no approved treatment.
Researchers used AI to redesign antibody fragments so they can work inside cells — a long-standing hurdle — and aimed them at the toxic proteins behind Alzheimer’s, Parkinson’s and motor neurone disease.
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.
PIKTOR, an oral combination that hits the PI3K/AKT/mTOR pathway, won fast-track status alongside chemotherapy for endometrial cancer that has progressed despite prior treatment.
An observational analysis of more than 31,000 patients tied one widely used class of blood-pressure pills to a 33% higher risk of serious kidney events — though researchers stress it cannot prove cause.
In the Phase 3 SAFFRON trial, adding Hutchmed’s Orpathys to Tagrisso delayed progression and extended overall survival in EGFR-mutated lung cancer that had developed a MET-driven resistance.
While the industry chases GLP-1 agonists for weight loss, Amylyx went the other way — and its GLP-1 antagonist cut severe hypoglycemic events by 55% in a late-stage trial.
After shelving its sickle cell program over safety concerns, Fulcrum is combining with Slate Medicines in a reverse merger built around a next-generation migraine drug.
Researchers paired live malaria parasites with a drug that stops them in the liver, converting infectious bites into immunizing events that produced durable protection in animals.